Video

Dr. Kebriaei on the Iomab-B Clinical Trial

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses the SIERRA clinical trial, in which patients over the age of 55 with acute myeloid leukemia (AML) are receiving treatment with a radiolabeled anti-CD45 antibody known as Iomab-B or conventional therapy as a preconditioning regimen before allogeneic hematopoietic cell transplantation.

The targeted administration of radiation helps to treat older patients with AML, as it is a less intense therapy, notes Kabriaei. This reduced intensity is especially important for older patients, who tend to have less tolerance for toxicities. Iomab-B offers a novel therapy for this population of patients, she adds.

<<<

View more from the 2017 BMT Tandem Meetings

Related Videos
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Francine Foss, MD